NAD+ Research Guide: Cellular Energy, Sirtuin Activation & Longevity Mechanisms

For laboratory and research use only. Not for human consumption.

Middle age. Half your NAD+ — gone. It gets worse. Up to 80% depleted between your twenties and sixty. That’s not a minor biomarker shift. That’s a wholesale biochemical collapse.

NAD+ touches over 500 enzymatic reactions. Burns fuel (glycolysis, TCA cycle, oxidative phosphorylation). And it vanishes with every passing decade.

A lot to cover.

What Is NAD+?

Arthur Harden boiled yeast extract in 1906. Something in the filtrate made fermentation go faster. Small molecule. Heat-stable. They called it a “cozymase.” We call it NAD+.

Two nucleotides linked through phosphate groups — NMN on one side, AMP on the other. Deceptively simple for a molecule that participates in hundreds of reactions.

• Molecular Formula: C₂₁H₂₇N₇O₁₄P₂
• Molecular Weight: 663.43 g/mol
• CAS Number: 53-84-9

Primary role: electron shuttle. Grabs hydride ions off metabolic substrates in glycolysis, TCA, and oxidative phosphorylation. Becomes NADH. The ratio between NAD⁺ and NADH tells cells what metabolic gear they’re running. High = active oxidation. Low = reduced state (Cantó et al., 2015; PMID: 25662603).

But the aging field doesn’t care about the electron shuttle role. It cares about what happens when NAD+ gets consumed. Three enzyme families — sirtuins, PARPs, CD38 — literally break NAD+ apart. They crack the nicotinamide-ADP-ribose bond and use the fragments for regulatory reactions (Imai & Guarente, 2014; PMID: 24786174).

This is the part people miss. NAD+ isn’t just an electron carrier. It’s expendable fuel for the cell’s highest-priority maintenance systems. And when levels drop with age, those systems starve.

The sirtuin family. SIRT1 through SIRT7. Deacylases that yank acetyl and acyl groups off proteins — but only when NAD+ is available to power the reaction. Pull NAD+ away and sirtuin activity collapses. That’s not metaphor; it’s enzymology.

Sirtuin	Where	What It Does	Standout Data
SIRT1	Nucleus/Cytoplasm
SIRT2	Cytoplasm	Cell cycle control	Mitotic checkpoints, adipocyte biology
SIRT3	Mitochondria	Mitochondrial deacetylation	Turns on SOD2, respiratory chain.
SIRT4	Mitochondria	ADP-ribosylation
SIRT5	Mitochondria	Desuccinylation	Urea cycle, fatty acid oxidation
SIRT6	Nucleus	Transgenic overexpression → males lived longer (Kanfi, 2012)
SIRT7	Nucleolus	rDNA transcription

Here’s what makes this family so interesting for aging research. Four entirely different organisms. Not one pathway. A whole web of them — all gated by NAD+ availability.

PARPs: The NAD+ Budget Problem

PARP1 and PARP2 do 90% of PARP activity in mammalian cells. Crucial work. But incredibly expensive — measured in NAD+ molecules consumed.

Acute DNA damage can trigger PARP hyperactivation. When that happens? NAD+ reserves get torched. Rapidly. And every NAD+ molecule PARP burns is one the sirtuins can’t use.

Proof: PARP1 knockout mice. No PARP1 means no NAD+ drain from DNA repair. Chemical PARP inhibitors did the same thing. Block one NAD+ consumer, and the others feast.

This is the fundamental tension in NAD+ biology. PARPs, CD38, and sirtuins all compete for a limited NAD+ supply. A zero-sum game at the molecular level. Understanding who’s winning that competition at any given point in the aging process — that’s what drives the entire NAD+ repletion field (Mouchiroud et al., 2013; PMID: 23698361).

CD38 and the Age-Related NAD+ Collapse

CD38. Ectoenzyme. Chews through NAD+ and spits out cyclic ADP-ribose for calcium signaling. And its expression climbs — relentlessly — as organisms age. If you want a single culprit for age-related NAD+ loss, this is it.

The decline in numbers:

• ~50% of NAD+ gone by middle age (Yoshino et al., 2018; PMID: 29514064)
• Skin by 60: 50–80% depleted (Massudi et al., 2012; PMID: 22848760)
• Brain loses 10–25%. Liver about 30% (over-60 vs. under-45)
• Men drop faster, especially mid-life

Knockout experiment: remove CD38 entirely from mice. NAD+ stays elevated. SIRT1 cranks up. High-fat-diet metabolic damage? Protected (Barbosa et al., 2007; PMID: 17376880).

Why does CD38 increase with age? Blame inflammaging. Chronic low-grade inflammation. Fewer NAD+ molecules → more senescent cells → more inflammatory cytokines → higher CD38 expression → even less NAD+. A self-reinforcing spiral that accelerates with every year.

Mitochondria Can’t Run Without It

Every time the TCA cycle turns, it produces NADH. That NADH hands electrons to Complex I — the biggest, first complex in the electron transport chain. Kill that handoff and ATP production collapses. No NAD+ recycling, no energy. Full stop.

Three specific connections:

When Complex I is deficient, NADH piles up because it can’t pass electrons forward. Mitochondrial NAD+ crashes. SIRT3 goes dark. Tissue damage follows.

SIRT3 itself deacetylates subunits in both Complex I and Complex II. It’s the quality control enzyme for the respiratory chain. And it runs on NAD+. Low NAD+ means sloppy mitochondria.

Then there’s biogenesis — making entirely new mitochondria. SIRT1 deacetylates PGC-1α, which kicks off mitochondrial production. SIRT1 needs NAD+. So NAD+ levels control not just how well existing mitochondria work but how many new ones get built.

+.

Here’s where NAD+ goes from interesting chemistry to “maybe we can reverse aging.”

Worms

Give C. elegans NAD+ precursors and block PARPs. The worm sirtuin (sir-2.1) fires up. Mitochondria work better. The worms live longer. Simple experiment, clear result: busted NAD+ metabolism causes aging phenotypes. It’s not just correlated — fix the NAD+ and you fix the decline (Mouchiroud et al., 2013; PMID: 23698361).

Old Mice

Late-middle-age mice. NMN dissolved in drinking water at 500 mg/kg/day. Lipid profiles cleaned up. Mitochondria hummed again. The animals moved more. Organ after organ reversed its age-related slide.

One Gene, Longer Life

Extra SIRT6 copies? Male mice lived longer. Lower IGF-1. Just one sirtuin gene (Kanfi et al., 2012; PMID: 22367546). Target SIRT1 to the hypothalamus? Both sexes lived longer.

NMN vs. NR vs. Direct NAD+

The precursor question. Three molecules, three routes to the same destination.

	NMN	NR	Direct NAD+
MW	334 g/mol	255 g/mol	663 g/mol
Conversion Steps	One (NMNAT)	Two (NRK → NMNAT)	Zero. Already NAD+
Oral Route	Fast absorption, salvage pathway	Phosphorylated before conversion	Big molecule — parenteral routes studied

Straightforward, right? Fewer steps should mean faster NAD+ elevation. Except a 2025 Science Advances paper complicated the picture. Both NMN and NR, when taken orally, get mostly broken down to plain nicotinamide (NAM) in the gut and liver first. Then re-synthesized into NAD+ through the Preiss-Handler pathway. The precursors themselves spiked in blood within 15 minutes — gone by 60. Actual NAD+ elevation was slower and more sustained (Yaku et al., 2025; DOI: 10.1126/sciadv.adr1538).

So much for the “direct conversion” narrative. The body routes things its own way.

Direct NAD+ 500mg administration bypasses all of that. It is the finished molecule. No enzymatic middlemen. The catch: 663 Da is nearly double the size of NMN, which complicates absorption. Parenteral delivery solves that, oral delivery doesn’t. Pick your trade-off based on protocol needs.

Safety and Practical Considerations

Generally favorable safety profile across preclinical models. NMN at 100–500 mg/kg/day in mice showed no significant adverse findings in long-term studies (Mills et al., 2016).

Watch for:

• NAD⁺/NADH ratio matters for protocol design. The oxidized-to-reduced balance influences multiple pathways simultaneously. Don’t ignore it
• NAD+ degrades with light, heat, and pH extremes. Store properly or your measurements are artifacts

Regulatory Status

NAD+ is a research compound available for laboratory and investigational use. Not FDA-approved as a standalone agent. NAD+ and its precursors (NMN, NR) are available through research suppliers for preclinical work.

Research Availability

From Loti Labs:

• NAD+ 500mg — $99.99

Conclusion

NAD+ vanishes as we age. CD38 drives the loss. Sirtuins and PARPs fight over what remains. Mitochondria stall.

But give aging animals NAD+ back? Mitochondria fire up. Physical function returns. That’s the preclinical promise — and it’s consistent across worms, mice, and every model organism tested so far.

Open questions remain. Delivery optimization. Tissue-specific kinetics. How much PARP capacity do you sacrifice for sirtuin gains? What’s the circadian angle? Big questions. But NAD+ left the “speculative” category years ago. This is bedrock aging biology now.

For laboratory and research use only. Not for human consumption.

References

1. Imai S, Guarente L. NAD+ and sirtuins in aging and disease. Trends Cell Biol. 2014;24(8):464-471. PMID: 24786174
2. Cantó C, Menzies KJ, Auwerx J. Cell Metab. 2015;22(1):31-53. PMID: 26118927
3. Mouchiroud L, Houtkooper RH, Moullan N, et al. Cell. 2013;154(2):430-441. PMID: 23698361
4. Mills KF, Yoshida S, Stein LR, et al. Long-term NMN administration mitigates age-associated physiological decline in mice. Cell Metab. 2016;24(6):795-806. PMID: 28068222
5. Kanfi Y, Naiman S, Amir G, et al. Nature. 2012;483(7388):218-221. PMID: 22367546
6. Satoh A, Brace CS, Rensing N, et al. Sirt1 extends life span and delays aging in mice through DMH and LH regulation. Cell Metab. 2013;18(3):416-430. PMID: 23746838
7. Bai P, Cantó C, Oudart H, et al. Cell Metab. 2011;13(4):461-468. PMID: 21459330
8. Barbosa MT, Soares SM, Novak CM, et al. CD38 is a key regulator of diet-induced body weight gain. Biochem J. 2007;403(Pt 3):573-581. PMID: 17376880
9. Gibson BA, Kraus WL. New insights into poly(ADP-ribose) and PARPs. Nat Rev Mol Cell Biol. 2012;13(7):411-424. PMID: 22713970
10. Yoshino J, Baur JA, Imai S. Cell Metab. 2018;27(3):513-528. PMID: 29514064
11. Massudi H, Grant R, Braidy N, et al. Age-associated changes in oxidative stress and NAD+ metabolism in human tissue. PLoS One. 2012;7(7):e42357. PMID: 22848760
12. Karamanlidis G, Lee CF, Garcia-Menendez L, et al. Complex I deficiency increases protein acetylation and accelerates heart failure. Cell Metab. 2013;18(2):239-250. PMID: 23931755
13. Haigis MC, Sinclair DA. Mammalian sirtuins: biological insights and disease relevance. Annu Rev Pathol. 2010;5:253-295. PMID: 20078221
14. Yaku K, et al. NR and NMN facilitate NAD+ synthesis via enterohepatic circulation. Sci Adv. 2025. DOI: 10.1126/sciadv.adr1538